Dr. Pinter-Brown on Treatment Expectations in CTCL

Lauren Pinter-Brown, MD
Published Online: Tuesday, April 2, 2013
Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses physician and patient expectations when treating cutaneous T-cell lymphoma (CTCL).

As with other oncologic conditions, if a patient is being treated with a drug and progresses, it is obvious that the drug is ineffective. In patients with CTCL, physicians have to be aware of the time to response for particular treatments, as they're not identical.

In the case of bexarotene, the time to response is four months, which causes physicians and patients to set appropriate expectations as the patient's condition will not worsen but it will not get better for many months. Fortunately, monitoring CTCL does not require scans or blood tests: physicians simply have to monitor skin lesions as time passes.

Online CME Activities
Free CME from PER
Update From ASCO: Advances in Immunotherapy for Non–Small Cell Lung Cancer and Melanoma
Updates in Supportive Care From ASCO 2014
Community Practice Connections: Personalization of NSCLC Therapy: Novel Breakthroughs in Patient Care
Cancer Summaries and Commentaries: Update from Chicago – Advanced Gastrointestinal Cancers
More Reading
Publications
$auto_registration$